Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$196,000.

  • Mereo BioPharma Group's Gains from Investment Securities fell 432.20% to -$196,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 783.80%. This contributed to the annual value of -$1.8 million for FY2024, which is 30.89% down from last year.
  • Mereo BioPharma Group's Gains from Investment Securities amounted to -$196,000 in Q3 2025, which was down 294.06% from $101,000 recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Gains from Investment Securities high stood at $448,000 for Q1 2024, and its period low was -$2.3 million during Q4 2024.
  • In the last 3 years, Mereo BioPharma Group's Gains from Investment Securities had a median value of -$68,500 in 2024 and averaged -$359,800.
  • In the last 5 years, Mereo BioPharma Group's Gains from Investment Securities skyrocketed by 182.66% in 2024 and then crashed by 432.20% in 2025.
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Gains from Investment Securities stood at -$897,000 in 2023, then tumbled by 159.31% to -$2.3 million in 2024, then slumped by 432.20% to -$196,000 in 2025.
  • Its last three reported values are -$196,000 in Q3 2025, $101,000 for Q2 2025, and -$416,000 during Q1 2025.